Evaluation of an array-based method for human papillomavirus detection and genotyping in comparison with conventional methods used in cervical cancer screening

Journal of Clinical Microbiology

Volumn 47, Issue 7, 2009, Pages 2165-2169

  García Sierra, Nerea ^a   Martró, Elisa ^a,b   Castellà, Eva ^a   Llatjós, Mariona ^a   Tarrats, Antoni ^a   Bascuñana, Elisabet ^a,b   Díaz, Rosana ^a   Carrasco, María ^a   Sirera, Guillem ^c   Matas, Lurdes ^a,b   Ausina, Vicente ^a,d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c Lluita Contra la SIDA Foundation   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MOLECULAR HYBRIDIZATION; PAPANICOLAOU TEST; POPULATION RESEARCH; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 67650074205     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00402-09     Document Type: Article

References (24)

1. Belinson, J., Y. L. Qiao, R. Pretorius, W. H. Zhang, P. Elson, L. Li, Q. J. Pan, C. Fischer, A. Lorincz, and D. Zahniser. 2001. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol. Oncol. 83:439-444.
2. Bosch, F. X., X. Castellsague, and S. de Sanjosé 2008. HPV and cervical cancer: screening or vaccination? Br. J. Cancer 98:15-21.
3. Bosch, F. X., A. Lorincz, N. Munoz, C. J. Meijer, and K. V. Shah. 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55:244-265.
4. Brink, A. A., P. J. Snijders, and C. J. Meijer. 2007. HPV detection methods. Dis. Markers 23:273-281.
5. Castle, P. E., M. Schiffman, R. D. Burk, S. Wacholder, A. Hildesheim, R. Herrero, M. C. Bratti, M. E. Sherman, and A. Lorincz. 2002. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol. Biomarkers Prev. 11:1394-1399.
6. Chacon, J., I. Sanz, M. D. Rubio, M. L. de la Morena, E. Diaz, M. L. Mateos, and F. Baquero. 2007. Detection and genotyping of high-risk human papillomavirus in cervical specimens. Enferm. Infecc. Microbiol. Clin. 25:311-316. (In Spanish.)
7. Dehn, D., K. C. Torkko, and K. R. Shroyer. 2007. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer 111:1-14.
8. Gravitt, P. E., L. J. van Doorn, W. Quint, M. Schiffman, A. Hildesheim, A. G. Glass, B. B. Rush, J. Hellman, M. E. Sherman, R. D. Burk, and S. S. Wang. 2007. Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions. J. Clin. Microbiol. 45:3245-3250.
9. Harper, D. M., E. L. Franco, C. Wheeler, D. G. Ferris, D. Jenkins, A. Schuind, T. Zahaf, B. Innis, P. Naud, N. S. De Carvalho, C. M. Roteli-Martins, J. Teixeira, M. M. Blatter, A. P. Korn, W. Quint, and G. Dubin. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765.
10. Khan, M. J., P. E. Castle, A. T. Lorincz, S. Wacholder, M. Sherman, D. R. Scott, B. B. Rush, A. G. Glass, and M. Schiffman. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97:1072-1079.
11. Kovacs, K., A. D. Varnai, M. Bollmann, A. Bankfalvi, M. Szendy, N. Speich, C. Schmitt, L. Pajor, and R. Bollmann. 2008. Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: a 7.5-year longitudinal study in a routine cytology-based screening population in West Germany. J. Med. Virol. 80:1814-1823.
12. Lorincz, A. T., and R. M. Richart. 2003. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch. Pathol. Lab. Med. 127:959-968.
13. Molijn, A., B. Kleter, W. Quint, and L. J. van Doorn. 2005. Molecular diagnosis of human papillomavirus (HPV) infections. J. Clin. Virol. 32(Suppl. 1):S43-S51.
14. Muñoz, N., F. X. Bosch, S. S. de, R. Herrero, X. Castellsague, K. V. Shah, P. J. Snijders, and C. J. Meijer. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348: 518-527.
15. Parkin, D. M., F. Bray, J. Ferlay, and P. Pisani. 2005. Global cancer statistics, 2002. CA Cancer J. Clin. 55:74-108.
16. Parkin, D. M., F. I. Bray, and S. S. Devesa. 2001. Cancer burden in the year 2000: the global picture. Eur. J. Cancer 37(Suppl. 8):S4-S66.
17. Poljak, M., I. J. Marin, K. Seme, and A. Vince. 2002. Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J. Clin. Virol. 25(Suppl. 3):S89-S97.
18. Sandri, M. T., P. Lentati, E. Benini, P. Dell'Orto, L. Zorzino, F. M. Carozzi, P. Maisonneuve, R. Passerini, M. Salvatici, C. Casadio, S. Boveri, and M. Sideri. 2006. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J. Clin. Microbiol. 44:2141-2146.
19. Schiffman, M. H., H. M. Bauer, R. N. Hoover, A. G. Glass, D. M. Cadell, B. B. Rush, D. R. Scott, M. E. Sherman, R. J. Kurman, S. Wacholder, C. K. Stanton, and M. M. Manos. 1993. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 85:958-964.
20. Solomon, D., D. Davey, R. Kurman, A. Moriarty, D. O'Connor, M. Prey, S. Raab, M. Sherman, D. Wilbur, T. Wright, Jr., and N. Young. 2002. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287:2114-2119.
21. Stanley, M. 2006. Immune responses to human papillomavirus. Vaccine 24(Suppl. 1):S16-S22.
22. Strickler, H. D., J. M. Palefsky, K. V. Shah, K. Anastos, R. S. Klein, H. Minkoff, A. Duerr, L. S. Massad, D. D. Celentano, C. Hall, M. Fazzari, S. Cu-Uvin, M. Bacon, P. Schuman, A. M. Levine, A. J. Durante, S. Gange, S. Melnick, and R. D. Burk. 2003. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J. Natl. Cancer Inst. 95:1062-1071.
23. Villa, L. L., R. L. Costa, C. A. Petta, R. P. Andrade, K. A. Ault, A. R. Giuliano, C. M. Wheeler, L. A. Koutsky, C. Malm, M. Lehtinen, F. E. Skjeldestad, S. E. Olsson, M. Steinwall, D. R. Brown, R. J. Kurman, B. M. Ronnett, M. H. Stoler, A. Ferenczy, D. M. Harper, G. M. Tamms, J. Yu, L. Lupinacci, R. Railkar, F. J. Taddeo, K. U. Jansen, M. T. Esser, H. L. Sings, A. J. Saah, and E. Barr. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6:271-278.
24. Walboomers, J. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, K. V. Shah, P. J. Snijders, J. Peto, C. J. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.